Skip to main content
. 2018 Oct 15;3(3):146–159. doi: 10.1002/jin2.51

Figure 6.

Figure 6

Effect of PEG‐DOX nanocarriers administered by different routes on tumour growth in orthotopic breast cancer model. F344 retired female breeder rats were inoculated with 13762 Mat B III cells (2.5 × 105 cells/rat) into the fourth mammary duct. Two days later, the rats received either intraductal (ID) treatment into the same duct or intravenous (IV) treatment with DOX or PEG‐DOX nanocarriers at doses of 0.83 mg/kg DOX equivalents. (A) Control group, rats received no treatment; (B) rats received intraductal treatment; (C) rats received intravenous treatment. Each point represents the mean ± standard deviation (n = 3–9). DOX, doxorubicin; PEG, poly(ethylene glycol).